XML 14 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows used in operating activities:    
Net loss $ (9,075) $ (9,506)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 524 477
Amortization of deferred financing costs and debt discount 20 160
Share-based compensation expense 422 428
Accretion of discount on short-term investments (70)  
Non-cash financing expense 3,545  
Change in fair value of warrants (5,654)  
Loss on disposal of property and equipment   2
Amortization of operating lease right-of-use assets 96 86
Stock issued for research and development   75
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Grant receivable   (91)
Other current assets 704 3,190
Accounts payable and accrued expenses 1,326 (4,061)
Change in operating lease liabilities (97) (87)
Deferred grant liability (1,084) (1,643)
Net cash used in operating activities (9,343) (10,970)
Cash flows used in investing activities:    
Purchases of property and equipment (135) (118)
Redemption of short-term investments 3,650  
Purchase of short-term investments (7,145)  
Purchase of intangible assets (545)  
Net cash used in investing activities (4,175) (118)
Cash flows provided by financing activities:    
Principal payments of term loan obligation (3,996) (1,206)
Proceeds from credit facility 3,292  
Purchase of treasury stock (374)  
Proceeds from sale of common stock, net of offering costs of $0.2 million   5,180
Proceeds from sale of common stock, warrants and pre-funded warrants, net 7,265 0
Net cash provided by financing activities 6,187 3,974
Net decrease in cash and cash equivalents (7,331) (7,114)
Cash and cash equivalents at beginning of period 8,554 18,120
Cash and cash equivalents at end of period 1,223 11,006
Cash paid during period for:    
Interest 32 186
Supplemental schedule of non-cash investing and financing activities:    
Unpaid offering cost $ 0 1
Right-of-use assets obtained in exchange for operating lease liability   71
Common stock issued in payment for in process research and development   $ 75